scispace - formally typeset
T

Thomas Westerling

Researcher at Harvard University

Publications -  14
Citations -  932

Thomas Westerling is an academic researcher from Harvard University. The author has contributed to research in topics: Estrogen receptor & Estrogen. The author has an hindex of 12, co-authored 14 publications receiving 735 citations. Previous affiliations of Thomas Westerling include Tufts Medical Center & Brigham and Women's Hospital.

Papers
More filters
Journal ArticleDOI

Growth factor stimulation induces a distinct ERα cistrome underlying breast cancer endocrine resistance

TL;DR: It is shown that the EGF-induced ERα genomic targets, its cistromes, are distinct from those induced by estrogen in a process dependent on the transcription factor AP-1, and this provides a potential molecular explanation for the endocrine therapy resistance seen in ERα-positive breast cancers that overexpress ERBB2.
Journal ArticleDOI

Feedback Regulation of Transcriptional Termination by the Mammalian Circadian Clock PERIOD Complex

TL;DR: The transcriptional feedback mechanism at the heart of the mammalian circadian clock was explored, finding that mouse PER complexes included RNA helicases DDX5 and DHX9, active RNA polymerase II large subunit, Per and Cry pre-mRNAs, and SETX, a helicase that promotes transcriptional termination.
Journal ArticleDOI

Estrogen receptor prevents p53-dependent apoptosis in breast cancer

TL;DR: This work has addressed the mechanism by which ER antagonizes the proapoptotic function of p53 and suggested an improved strategy for the treatment of ER+ breast cancer using antagonists that completely block ER action together with drugs that activate p53-mediated cell death.
Journal ArticleDOI

Vitamin D receptor regulates autophagy in the normal mammary gland and in luminal breast cancer cells

TL;DR: It is revealed that vitamin D and its receptor regulate autophagy in both normal mammary epithelial cells and luminal BCs, and a potential mechanism underlying the link between vitamin D levels and BC risk is suggested.